Stability Studies SOP

The purpose of this SOP is to provide a standardized approach for conducting stability studies for modified-release products in compliance with US FDA and ICH guidelines to ensure their safety, quality, and efficacy throughout their shelf life.
Click to read the full article.

The purpose of this SOP is to provide a standardized procedure for documenting stability studies in support of New Drug Applications (NDAs) to the US FDA to ensure compliance with regulatory requirements.
Click to read the full article.

The purpose of this SOP is to provide a standardized procedure for developing stability study reports for Abbreviated New Drug Applications (ANDAs) to the US FDA, ensuring compliance with regulatory requirements.
Click to read the full article.

The purpose of this SOP is to provide a standardized procedure for conducting stability testing of new dosage forms in compliance with ICH Q1C guidelines to ensure their quality, safety, and efficacy over their intended shelf life.
Click to read the full article.

The purpose of this SOP is to provide a standardized approach for managing stability testing following post-approval changes to drug substances and products in compliance with US FDA guidelines.
Click to read the full article.

The purpose of this SOP is to provide a standardized procedure for conducting stability studies in compliance with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) guidelines to ensure the safety, quality, and efficacy of drug products.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for preparing a stability protocol for drug substances and drug products in compliance with the ICH Q1A(R2) guidelines. This SOP ensures that the stability protocol is comprehensive, clear, and in line with regulatory requirements.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to outline the procedure for conducting stability studies of drug products in compliance with the US FDA Code of Federal Regulations (CFR) Title 21. This SOP ensures that the stability data generated is suitable for supporting product quality, safety, and efficacy throughout the shelf life as per US FDA requirements.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to define the process for conducting stability studies for biological drug substances and products in accordance with the US FDA guidelines. This SOP aims to ensure the generation of reliable stability data to support the quality, safety, and efficacy of biologics throughout their shelf life.
Click to read the full article.

The purpose of this Standard Operating Procedure (SOP) is to provide guidance on identifying, investigating, and resolving stability issues in Abbreviated New Drug Application (ANDA) submissions to the United States Food and Drug Administration (US FDA). This SOP ensures that any stability-related issues are adequately addressed to facilitate approval.
Click to read the full article.